Review Article
Open Access
Chimeric Vaccine Strategies Targeting Propionibacterium acnes: Prospects and Preclinical Insights
Qing Wei*
Department of Bioinformatics and Biological Statistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, PR China
Wei Q. Chimeric Vaccine Strategies Targeting Propionibacterium acnes: Prospects and Preclinical Insights, Accounts of Biotechnology Research. 2024, Vol. 12 No. 1: 102
Abstract
Acne vulgaris is one of the most prevalent dermatological disorders globally,
affecting up to 85% of adolescents and young adults. Propionibacterium acnes
plays a central role in acne pathogenesis through its virulence factors, including
sialidase and CAMP (Christie-Atkins-Munch-Petersen) factor. Current treatments,
including antibiotics and topical therapies, often fail due to resistance and
recurrence, highlighting the need for preventive strategies such as vaccination.
This review explores advances in recombinant protein-based vaccine candidates
targeting P. acnes, emphasizing chimeric constructs that combine multiple
antigens to enhance immunogenicity. Preclinical studies in murine models indicate
that these vaccines can elicit strong humoral and cellular immune responses,
reduce inflammation, and provide proof-of-concept for future clinical translation.
Challenges in antigen selection, safety, and delivery methods are discussed, and
directions for future research are highlighted.
affecting up to 85% of adolescents and young adults. Propionibacterium acnes
plays a central role in acne pathogenesis through its virulence factors, including
sialidase and CAMP (Christie-Atkins-Munch-Petersen) factor. Current treatments,
including antibiotics and topical therapies, often fail due to resistance and
recurrence, highlighting the need for preventive strategies such as vaccination.
This review explores advances in recombinant protein-based vaccine candidates
targeting P. acnes, emphasizing chimeric constructs that combine multiple
antigens to enhance immunogenicity. Preclinical studies in murine models indicate
that these vaccines can elicit strong humoral and cellular immune responses,
reduce inflammation, and provide proof-of-concept for future clinical translation.
Challenges in antigen selection, safety, and delivery methods are discussed, and
directions for future research are highlighted.
Keywords
Acne vulgaris; Propionibacterium acnes; CAMP factor; Sialidase; Recombinant protein; Vaccine development; Immunotherapy.
Full text content is not available right now.